Application in general practice of treatment guidelines for patients with dyslipidaemia: The RESPECT study

Archives of Cardiovascular Diseases

Volumn 101, Issue 11-12, 2008, Pages 715-721

  Cacoub, Patrice ^a   Gousse, Elisabeth Tocque Le ^b   Fabry, Caroline ^b   Hermant, Sophie ^c   Petzold, Lïc ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Laborotoire Astra Zeneca   (France)

^c Excip   (France)

^d Axonal Biostatem   (France)

Author keywords

Cardiovascular disease; Cholesterol; Dyslipidemia; General practice; Risk factor

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; FEMALE; FRANCE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; RISK ASSESSMENT;

EID: 58049211586     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.09.011     Document Type: Article

References (24)

1. Murray C, Lopez A, eds. The World Health Report 2002: Reducing risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002, p. 230.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet 1994;334:1383-9.
3. Shepherd J, et al., The West of Scotland coronary prevention study group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. The long-term intervention with pravastattn in ischemic disease (LIPID) study group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and broad range of initiated cholesterol levels. N Eng J Med 1998;339:1349-57.
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled group. Lancet 2002;360:7-22.
6. National Institutes of Health (NIH). National Heart, Lung, and Blood Institute (NHLBI). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication 02-5215; 2002. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/ atp3full.pdf. Accessed June 5, 2007.
7. The SPOT studyFerrieres J, et al. Biochemical evaluation of the results of lipid regulating treatment in France. Arch Mal Coeur 2005;98:58-62.
8. National Agency of Health Accreditation and Evaluation (ANAES). Guidelines for screening and biological diagnosis of dyslipidemia in primary prevention. ANAES; January 2000. Available at http://www.has-sante.fr/portail/display.jsp?id=c_271870.
9. French Health Products Safety Agency - Agence française de sécurité sanitaire des produits de santé (AFSSAPS). Therapeutic management of dyslipidemic patients; March 2005. Available at http://agmed.sante.gouv.fr/pdf/5/rbp/dysreco.pdf.
10. National Agency of Health Accreditation and Evaluation (ANAES). Clinical Practice Guidelines. Management of adults with essential hypertension - 2005 update; July 2005. Available at http://www.has-sante.fr/portail/ display.jsp?id=c_272459.
11. Rudnichi A, Safar M, Asmar R, Guize L, Benetos A. Prevalence of cardiovascular risk factors in a French population. J Hypertens 1998;16:S85-90.
12. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
13. Ferrieres J, Elbaz M, Maupas E, Carrie D, Puel J. Inadequate management of dyslipidemic patients in France. Results of the Odysse study. Arch Mal Coeur 2004;97: 187-93.
14. Mc Bride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158: 1238-44.
15. The PRAGMA studyAmouyel P, et al. Management of dyslipidemia diagnosed in general practice in France. Arch Mal Coeur 2001;94:1045-53.
16. Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 2007 Spring;5(2):91-6.
17. Sever PS, Dahlöf B, Poulter NR, et al., the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower than average cholesterol concentrations, in the Anglo Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361: 1149-58.
18. Heart Protection Study Collaborative Group. HPSCG. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
19. Study EUROASPIRE Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J 1997;18: 1569-82.
20. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995-1001.
21. Cambien F, Richard JL, Ducimetiere P, Warnet JM, Kahn J. The Paris Cardiovascular Risk Factor Prevention Trial. Effects of two years of intervention in a population of young men. J Epidemiol Community Health 1981;35:91-7.
22. National Cholesterol Education Program (NCEP). Third Report of the NCEP Expert Panel on Detection, Evaluation and Treatment of High Blood cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;17:3143-2.
23. Marques-Vidal P, Evans AE, Cambou JP, et al. Awareness and control of hypertension and hypercholesterolemia in France and Northern Ireland. Q J Med 1997;90:341-5.
24. Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 2006;185:58-64.